Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|December 11, 2023
Protection against lung pathology during obesity-accelerated ageing in mice by the parasitic worm product ES-62Margaret M Harnett, Felicity E Lumb, Jenny Crowe, et al.
Bioorganic & Medicinal Chemistry Letters|June 29, 2016
An evaluation of Minor Groove Binders as anti-lung cancer therapeuticsFraser J Scott, Mireia Puig-Sellart, Abedawn I Khalaf, et al.
Physical Chemistry Chemical Physics : PCCP|February 11, 2010
A detailed binding free energy study of 2:1 ligand-DNA complex formation by experiment and simulationWitcha Treesuwan, Kitiyaporn Wittayanarakul, Nahoum G Anthony, et al.
Chembiochem : a European Journal of Chemical Biology|July 22, 2014
Recognition of the DNA minor groove by thiazotropsin analoguesHasan Y Alniss, Marie-Virginie Salvia, Mykhailo Sadikov, et al.
European Journal of Medicinal Chemistry|September 6, 2012
Design, synthesis and antibacterial activity of minor groove binders: the role of non-cationic tail groupsAbedawn I Khalaf, Claire Bourdin, David Breen, et al.
Journal of Medicinal Chemistry|November 18, 2009
Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniasesLindsay B Tulloch, Viviane P Martini, Jorge Iulek, et al.
Organic & Biomolecular Chemistry|July 11, 2009
Diversity oriented syntheses of fused pyrimidines designed as potential antifolatesColin L Gibson, Judith K Huggan, Alan Kennedy, et al.
Frontiers in Immunology|September 15, 2022
The parasitic worm product ES-62 protects the osteoimmunology axis in a mouse model of obesity-accelerated ageingMargaret M Harnett, James Doonan, Felicity E Lumb, et al.
Journal of Medicinal Chemistry|July 10, 2014
Structure-based design and synthesis of antiparasitic pyrrolopyrimidines targeting pteridine reductase 1Abedawn I Khalaf, Judith K Huggan, Colin J Suckling, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacyLerato Hlaka, Michael-Jon Rosslee, Mumin Ozturk, et al.
Pageof 8